RESUMEN
Using the concepts of "duration" and "temporal patterns," this paper discusses how key steps during sampling change, if researchers take temporality seriously: When defining cases, scholars have to select a suitable temporal scale and reflect on possible changes of boundaries and properties of cases. When defining the population or field, researchers need to set an appropriate time frame and define periods within this time frame to be analyzed. When selecting the actual cases for analysis, researchers have to choose an appropriate sampling procedure, decide upon relevant periods of analysis as well as the number of points in time to be analyzed.
En utilisant les concepts de "durée" et de "modèles temporels," cet article examine comment les étapes clés du processus d'échantillonnage changent, quand la temporalité est prise au sérieux: en déterminant leur cas d'étude, les chercheurs doivent choisir une échelle temporelle appropriée et réfléchir aux changements possibles de la démarcation et des propriétés des cas. En définissant la population ou le domaine, les chercheurs ont besoin de fixer un cadre temporel et des intervalles de temps en son sein. En sélectionnant les cas, les chercheurs doivent choisir une procédure d'échantillonnage, déterminer les périodes d'analyse et le nombre de points dans le temps.
RESUMEN
Cell-autonomous induction of type I interferon must be stringently regulated. Rapid induction is key to control virus infection, whereas proper limitation of signaling is essential to prevent immunopathology and autoimmune disease. Using unbiased kinome-wide RNAi screening followed by thorough validation, we identified 22 factors that regulate RIG-I/IRF3 signaling activity. We describe a negative-feedback mechanism targeting RIG-I activity, which is mediated by death associated protein kinase 1 (DAPK1). RIG-I signaling triggers DAPK1 kinase activation, and active DAPK1 potently inhibits RIG-I stimulated IRF3 activity and interferon-beta production. DAPK1 phosphorylates RIG-I in vitro at previously reported as well as other sites that limit 5'ppp-dsRNA sensing and virtually abrogate RIG-I activation.
Asunto(s)
Proteínas Quinasas Asociadas a Muerte Celular/metabolismo , ARN Interferente Pequeño/genética , Receptores de Ácido Retinoico/metabolismo , Células A549 , Animales , Células Cultivadas , Retroalimentación Fisiológica , Células HEK293 , Humanos , Ratones , Fosforilación , Proteínas Quinasas/metabolismo , Transducción de SeñalRESUMEN
Adult bone mass is controlled by the bone formation repressor sclerostin (SOST). Previously, we have shown that intermittent parathyroid hormone (PTH) bone anabolic therapy involves SOST expression reduction by inhibiting myocyte enhancer factor 2 (MEF2), which activates a distant bone enhancer. Here, we extended our SOST gene regulation studies by analyzing a role of class I and IIa histone deacetylases (HDACs), which are known regulators of MEF2s. Expression analysis using quantitative PCR (qPCR) showed high expression of HDACs 1 and 2, lower amounts of HDACs 3, 5, and 7, low amounts of HDAC4, and no expression of HDACs 8 and 9 in constitutively SOST-expressing UMR106 osteocytic cells. PTH-induced Sost suppression was associated with specific rapid nuclear accumulation of HDAC5 and co-localization with MEF2s in nuclear speckles requiring serine residues 259 and 498, whose phosphorylations control nucleocytoplasmic shuttling. Increasing nuclear levels of HDAC5 in UMR106 by blocking nuclear export with leptomycin B (LepB) or overexpression in transient transfection assays inhibited endogenous Sost transcription and reporter gene expression, respectively. This repressor effect of HDAC5 did not require catalytic activity using specific HDAC inhibitors. In contrast, inhibition of class I HDAC activities and expression using RNA interference suppressed constitutive Sost expression in UMR106 cells. An unbiased comprehensive search for involved HDAC targets using an acetylome analysis revealed several non-histone proteins as candidates. These findings suggest that PTH-mediated Sost repression involves nuclear accumulation of HDAC inhibiting the MEF2-dependent Sost bone enhancer, and class I HDACs are required for constitutive Sost expression in osteocytes.
Asunto(s)
Proteínas Morfogenéticas Óseas/genética , Regulación de la Expresión Génica/genética , Marcadores Genéticos/genética , Histona Desacetilasas/genética , Acetilación/efectos de los fármacos , Animales , Línea Celular Tumoral , Núcleo Celular/efectos de los fármacos , Núcleo Celular/metabolismo , Electroforesis en Gel de Poliacrilamida , Ácidos Grasos Insaturados/farmacología , Regulación de la Expresión Génica/efectos de los fármacos , Proteínas Fluorescentes Verdes/genética , Proteínas Fluorescentes Verdes/metabolismo , Inhibidores de Histona Desacetilasas/farmacología , Histona Desacetilasas/metabolismo , Humanos , Factores de Transcripción MEF2/genética , Factores de Transcripción MEF2/metabolismo , Microscopía Confocal , Microscopía Fluorescente , Mutación , Osteocitos/efectos de los fármacos , Osteocitos/metabolismo , Hormona Paratiroidea/farmacología , Interferencia de ARN , Ratas , Reacción en Cadena de la Polimerasa de Transcriptasa InversaRESUMEN
Autologous grafts are frequently needed for nasal septum reconstruction. Because they are only available in limited amounts, there is a need for new cartilage replacement strategies. Tissue engineering based on the use of autologous chondrocytes and resorbable matrices might be a suitable option. So far, an optimal material for nasal septum reconstruction has not been identified. The aim of our study was to provide the first evaluation of marine collagen for use in nasal cartilage repair. First, we studied the suitability of marine collagen as a cartilage replacement matrix in the context of in vitro three dimensional cultures by analyzing cell migration, cytotoxicity, and extracellular matrix formation using human and rat nasal septal chondrocytes. Second, we worked toward developing a suitable orthotopic animal model for nasal septum repair, while simultaneously evaluating the biocompatibility of marine collagen. Seeded and unseeded scaffolds were transplanted into nasal septum defects in an orthotopic rat model for 1, 4, and 12 weeks. Explanted scaffolds were histologically and immunohistochemically evaluated. Scaffolds did not induce any cytotoxic reactions in vitro. Chondrocytes were able to adhere to marine collagen and produce cartilaginous matrix proteins, such as collagen type II. Treating septal cartilage defects in vivo with seeded and unseeded scaffolds led to a significant reduction in the number of nasal septum perforations compared to no replacement. In summary, we demonstrated that marine collagen matrices provide excellent properties for cartilage tissue engineering. Marine collagen scaffolds are able to prevent septal perforations in an autologous, orthotopic rat model. This newly described experimental surgical procedure is a suitable way to evaluate new scaffold materials for their applicability in the context of nasal cartilage repair.